SALT LAKE
CITY, Sept. 21, 2023 /PRNewswire/ -- Sera
Prognostics Inc., The Pregnancy Company® (Nasdaq:
SERA), focused on improving maternal and neonatal health by
providing innovative pregnancy biomarker information to doctors and
patients, today announced that the company will present at the
upcoming Cantor Fitzgerald Global Healthcare Conference 2023 to be
held September 26-28, 2023 in
New York City.
Zhenya Lindgardt, Sera's interim President and
CEO, is scheduled to participate in a panel presentation on
September 26, 2023, at 9:20 a.m. ET. Due to the format of this event, a
webcast will not be available. Sera's management will also be
available for one-on-one meetings with investors.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics
company dedicated to improving the lives of women and babies
through precision pregnancy care. Sera's mission is to provide
early, pivotal pregnancy information to improve the health of
mothers and newborns, resulting in reductions in the costs of
healthcare delivery. Sera has a robust pipeline of innovative
diagnostic tests focused on the early prediction of preterm birth
risk and other complications of pregnancy. Sera's precision
medicine PreTRM® Test reports to a physician the
individualized risk of spontaneous premature delivery in a
pregnancy, enabling earlier proactive interventions in women with
higher risk. Sera Prognostics is headquartered in Salt Lake
City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37
weeks' gestation and is the leading cause of illness and death in
newborns. The 2022 March of Dimes Report Card shows that, for the
last four consecutive years, more than one in ten infants is born
prematurely. Prematurity is associated with a significantly
increased risk of major long-term medical complications, including
learning disabilities, cerebral palsy, chronic respiratory illness,
intellectual disability, seizures, and vision and hearing loss, and
can generate significant costs throughout the lives of affected
children. The annual health care costs to manage short- and
long-term complications of prematurity in the United
States were estimated to be approximately $25
billion for 2016.
About the PreTRM®
Test
The PreTRM® Test is the only broadly
validated, commercially available blood-based biomarker test that
provides an early, accurate and individualized risk prediction for
spontaneous preterm birth in asymptomatic singleton pregnancies.
The PreTRM® Test measures and analyzes proteins in the
blood that are highly predictive of preterm birth. The
PreTRM® Test permits physicians to identify, during the
weeks 18 through 20 of pregnancy, which women are at increased risk
for preterm birth and its complications, enabling more informed,
personalized clinical decisions based on each woman's individual
risk. The PreTRM® Test is ordered by a medical
professional.
Sera Prognostics, the Sera Prognostics logo, The
Pregnancy Company, and PreTRM are trademarks or registered
trademarks of Sera Prognostics, Inc. in the United
States and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements relating to the Company's
planned presentation and one-on-one meetings with investors at the
aforementioned investor conference; and the company's strategic
directives under the caption "About Sera Prognostics, Inc." These
"forward-looking statements" are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by
forward-looking statements. These risks and uncertainties include,
but are not limited to: net losses, cash generation, and the
potential need to raise more capital; revenues from the PreTRM Test
representing substantially all Company revenues to date; the need
for broad scientific and market acceptance of the PreTRM Test; a
concentrated number of material customers; our ability to introduce
new products; potential competition; our proprietary biobank;
critical suppliers; the COVID-19 pandemic and its potential
lingering impact on our operations, as well as the business or
operations of third parties with whom we conduct business;
estimates of total addressable market opportunity and forecasts of
market growth; potential third-party payer coverage and
reimbursement; new reimbursement methodologies applicable to the
PreTRM Test, including new CPT codes and payment rates for those
codes; changes in FDA regulation of laboratory-developed tests; the
intellectual property rights protecting our tests and market
position; and other factors discussed under the heading "Risk
Factors" contained in our Final Prospectus on Form S-1, which was
filed with the Securities and Exchange Commission on July 14, 2021, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q, Annual Reports on Form 10-K, or Current Reports on Form
8-K. All information in this press release is as of the date of the
release, and the Company undertakes no duty to update this
information unless required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-to-present-at-cantor-fitzgerald-global-healthcare-conference-2023-301934181.html
SOURCE Sera Prognostics, Inc.